Longevity & AgingResearch PaperOpen Access

NLRP3 inhibitor MCC950 eases nerve inflammation and demyelination in rat model of Guillain-Barré syndrome

In rats with autoimmune neuritis, blocking the NLRP3 inflammasome with MCC950 reduced paralysis, immune infiltration and myelin loss, and lowered IL-23/IL-17 signaling.

Friday, November 20, 2026 0 views
Published in J Inflamm Res
Glowing NLRP3 inflammasome ring complex being blocked by a small-molecule inhibitor beside a myelinated peripheral nerve fiber

Summary

Guillain-Barré syndrome (GBS) is an autoimmune attack on peripheral nerves, and some patients still end up disabled despite standard therapy. This study asked whether the NLRP3 inflammasome, an innate immune sensor that drives IL-1β and IL-18 release, contributes. In blood cells from 11 GBS patients versus 11 healthy controls, NLRP3, ASC and caspase-1 mRNA were higher. In Lewis rats with experimental autoimmune neuritis (6 per group), the NLRP3 inhibitor MCC950 lowered inflammasome markers in the sciatic nerve, improved clinical scores and nerve conduction, reduced CD4+ T cell and macrophage infiltration, limited myelin loss, and reduced IL-23 and IL-17A. This is a small rat study with short-term outcomes. It shows mechanism and function, not lifespan, and no human treatment data.

Detailed Summary

Guillain-Barré syndrome is the most common acute paralytic neuropathy. Plasma exchange or IVIG help, yet about 20% of patients keep mobility problems and 5-10% die. A treatment that targets the inflammatory machinery damaging peripheral nerve myelin would fill a real gap. This paper tests one candidate: the NLRP3 inflammasome, a protein complex that activates caspase-1 and releases the inflammatory cytokines IL-1β and IL-18.

The researchers first compared PBMC gene expression in 11 GBS patients and 11 age- and sex-matched healthy controls. NLRP3, ASC and caspase-1 mRNA were all higher in patients (p<0.001). They then used experimental autoimmune neuritis (EAN), induced in female Lewis rats by P2 peptide immunization, a standard GBS model. Eighteen rats were split into sham, EAN and EAN plus MCC950 groups (n=6 each). MCC950, a selective NLRP3 inhibitor, was given intraperitoneally at 10 mg/kg every other day from symptom onset (day 10) to day 24.

On mechanism, MCC950 lowered NLRP3, ASC, caspase-1, IL-1β and IL-18 at the mRNA and protein level in the sciatic nerve (qPCR n=3, Western blot and immunofluorescence n=4 per group). It also lowered IL-23 and IL-17A, which suggests the inflammasome feeds the Th17-related IL-23/IL-17 axis. On function, treated rats had lower clinical severity and cumulative scores, and better nerve conduction velocity and amplitude. End latency did not differ between groups. On tissue, MCC950 reduced inflammatory cell counts, CD4+ T cell and CD68+ macrophage infiltration, and myelin loss (luxol fast blue and MBP staining).

The data fit a model in which NLRP3 activation helps drive nerve inflammation and demyelination in this model, partly through IL-23/IL-17. But the link between the inflammasome and the IL-23/IL-17 axis is inferred from correlated expression changes after drug treatment. The study did not use genetic knockouts or pathway rescue to test causality. Lifespan was not studied.

Caveats are substantial. The human data are mRNA from 11 patients with one measurement type and no outcome link. The rat groups are small, only female rats were used, treatment was a single dose and schedule, and the report gives no safety data. Rat EAN only partly captures human GBS. MCC950 is a research compound, and no human GBS trial is reported here.

Key Findings

  • Human data: NLRP3, ASC and caspase-1 mRNA were higher in PBMCs of 11 GBS patients than in 11 matched controls.
  • Mechanism (rats): MCC950 reduced sciatic nerve NLRP3, ASC, caspase-1, IL-1β and IL-18, plus IL-23 and IL-17A (n=3-4/group).
  • Function (rats): MCC950 lowered clinical scores and improved nerve conduction velocity and amplitude (n=6/group); end latency did not differ.
  • Tissue (rats): treatment reduced CD4+ T cell and macrophage infiltration and limited myelin loss on LFB and MBP staining.
  • No lifespan, safety or human treatment data were reported; causality for the IL-23/IL-17 link was not tested genetically.

Methodology

Cross-sectional qPCR of PBMCs from 11 GBS patients and 11 matched healthy controls, plus a preclinical study in 18 female Lewis rats (sham, EAN, EAN+MCC950; n=6 each) with P2-peptide-induced neuritis. MCC950 10 mg/kg i.p. every other day from day 10 to 24; outcomes were clinical score, electrophysiology, histology, qPCR, Western blot and immunofluorescence, analyzed with t-tests or ANOVA with Tukey post hoc tests.

Study Limitations

Small samples (11 vs 11 patients; 3-6 rats per group), one sex, one dosing regimen, and a single animal model with no knockout or rescue experiments to prove the NLRP3-to-IL-23/IL-17 link. The human data are mRNA expression only, with no clinical correlation, and the study has no safety, long-term or lifespan data. The excerpt of the full text ends partway through the discussion, so any limitations stated there were not reviewed.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: